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metastatic breast cancer patients. Although the mean of ICER is
USD$135,701.69, the upper limit 95% CI suggests that Lapa-
tinib plus Capecitabine may be cost-ineffective. In addition, for
reasonable changes in key parameters, the combination therapy
becomes cost-ineffective.
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OBJECTIVE: An earlier economic evaluation showed that sor-
afenib was cost-effective compared to best supportive care (BSC)
in advanced renal cell carcinoma (RCC) (ASCO 2006). Recently
latest overall survival data from the Phase III TARGET study
was presented (ASCO 2007). The objective of this study was to
update the earlier economic model with the latest clinical data to
evaluate the cost-effectiveness of sorafenib+BSC versus BSC alone
in advanced RCC from a United States payer perspective.
METHODS: A Markov model was developed to project lifetime
survival and costs associated with sorafenib+BSC and BSC alone.
The model tracked patients with advanced RCC through three
states—PFS, progression, and death. Transition probabilities
varied for each three-month period and were obtained from the
TARGET data. Treatment effectiveness wasmeasured in life-years
gained. Resource utilization included drug, administration, phy-
sician visits, monitoring, and adverse events. Costs and survival
beneﬁts were discounted annually at 3%. Univariate and proba-
bilistic sensitivity analyses were conducted. RESULTS: Lifetime
per patient costs were $92,222 and $36,634 for sorafenib+BSC
and BSC alone, respectively. The incremental survival beneﬁt
with sorafenib+BSC was 0.88 life years. The incremental cost-
effectiveness ratio (ICER) of sorafenib+BSC versus BSC alone was
$63,219 per LYG. Results were sensitive to variation in sorafenib
and BSC survival after progression as well as sorafenib cost. There
was a 95% probability that sorafenib would be cost-effective vs.
BSC alone, using a threshold of $95,000 or less. CONCLUSION:
Updating the model with the most recent clinical trial data still
resulted in an incremental cost-effectiveness ratiowithin the estab-
lished threshold that society is willing to pay for cancer care (i.e.
$50,000–$100,000 per LY). Thus, consistent with earlier ﬁndings,
sorafenib+BSC appears to be cost-effective in the management of
advanced RCC.
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Current cost-effectiveness models of prostate cancer prevention
treatments examine the cost-effectiveness of preventative treat-
ments from the perspective of patient populations speciﬁc to
the treatment’s clinical trial. However, factors such as age, race,
family history, and prostate-speciﬁc antigen (PSA) levels are
major predictors of patient risk for developing prostate cancer.
OBJECTIVE: To create a model that examines potential clinical
and economic beneﬁts of preventative treatments in various
patient populations as deﬁned by prominent risk factors that
can be used to identify populations who might most beneﬁt
from preventative treatments. METHODS: Similar to previ-
ously published cost-effectiveness models for preventative
prostate cancer treatments, we developed a Markov model con-
sidering health states such as cancer-free, low-grade prostate
cancer, high-grade prostate cancer, and death. We also consider
the impact of avoiding benign prostate hyperplasia (BPH) and
decreased quality of life due to treatment-related adverse events
such as erectile dysfunction. Unlike previous models, our model
incorporates prostate cancer nomograms developed from an
analysis of a clinical database of at-risk men to estimate the
probability of high and low-grade prostate cancer and recur-
rence. Nomograms consider age, race, family history, free-to-
total PSA levels, PSA levels, and DRE results. The model can
also consider incidence of prostate cancer by age and race as
seen in SEER and high-grade prostatic intraepithelial neoplasia,
family history, PSA levels, previous biopsy results, and BPH
and DRE results as obtained from an analysis of the European
Study of Screening for Prostate Cancer database. RESULTS:
The model generates cost-effectiveness ratios identifying condi-
tions where preventative treatment is most cost effective versus
no preventative treatment. Ratios also identify speciﬁc patient
populations where preventative treatment has an advantage.
CONCLUSIONS: The model can incorporate patient risk
factor diversity to generate cost-effectiveness ratios speciﬁc to
different epidemiological populations; thus, better targeting
populations who might beneﬁt most from preventative
treatments.
PCN26
COST-EFFECTIVENESS MODELING OF COLORECTAL CANCER
10YEARS SCREENING USING COMPUTEDTOMOGRAPHIC
COLONOGRAPHYVERSUS COLONOSCOPY AND FECAL
OCCULT BLOODTESTS
Beresniak A1, Berger G2, Grenier P3, Poynard T3, Cadi M3,
Lucidarme O3
1Data Mining International, Geneva, Switzerland, 2University Pierre &
Marie Curie, Paris, France, 3University Pierre&Marie Curie, Paris,
France
OBJECTIVE: To assess the cost, effectiveness and cost-
effectiveness of three colorectal cancer (CRC) screening strate-
gies. METHODS: Simulation modeling was used to assess three
colorectal screening strategies of a virtual population over 50
years old: computed tomographic colonography (CTC), colonos-
copy and Fecal occult blood tests (FOBT). The model used a
simulation decision framework over a ten-years period. CTC is
repeated after 10 years if negative, and after three or ﬁve years if
positive with advanced or non-advanced adenoma respectively.
Colonoscopy is repeated after ten years if negative and after three
years or ﬁve years if positive with advanced or non advanced
adenoma respectively. FOBT is repeated every two years. Positive
CTC and FOBT are systematically conﬁrmed by colonoscopy.
The model computes the total cost and the incidence of CRC
after ten years of each screening strategy. RESULTS: Considering
a population adherence of 50%: colonoscopy being the only
screening strategy over 10 years is the most costly screening
strategy, €885 per individual, with 0.54% of remaining CRC.
CTC as only screening strategy over 10 years costs €543 per
individual with 0.18% of remaining CRC. FOBT as only screen-
ing strategy over 10 years costs €459 per individual with 0.18%
of remaining CRC. Mean cost-effectiveness ratios expressed as
cost-per-CRC-avoided are 544 with CTC, 890 with colonoscopy
and €460 with FOBT. CONCLUSION: This simulation model-
ing approach allows to take into account data variability and to
test various screening strategies. Further simulations have been
performed to study the impact of various screening program
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